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ABSTRAK
Prosedur endoskopi seringkali digunakan untuk mendiagnosis ataupun terapi. Endoskopi memiliki risiko 
baik saat prosedur maupun setelah prosedur. Pasien dengan terapi antitrombotik,  baik antiplatelet dan/atau 
antikoagulan, sebagai terapi penyakit yang mendasari memiliki risiko tinggi untuk perdarahan dan tromboemboli 
pada prosedur ini. Dokter perlu mempertimbangkan risiko dan keuntungan untuk melakukan penyesuaian pada 
terapi antitrombotik, dengan tujuan untuk menurunkan risiko perdarahan dan tromboemboli. Untuk prosedur 
risiko rendah, pada umumnya tidak memerlukan penyesuaian terapi. Untuk prosedur risiko tinggi, ada beberapa 
penyesuaian berdasarkan tipe medikasi dan kondisi pasien secara spesifik. European Society of Gastrointestinal 
Guidelines Endoscopy (ESGE) dan British Society of Gastrointestinal (BSG); American Society of Gastrointestinal 
Endoscopy (ASGE); dan terakhir Asian Pacific Association of Gastroenterology (APAGE) dan Asian Pacific 
Society for Digestive Endoscopy (APSDE) telah mengeluarkan panduan untuk membantu dokter dalam mengambil 
keputusan pada kasus pasien endoskopi dengan terapi antitrombotik. Artikel ini bertujuan untuk membandingkan 
setiap pedoman untuk memudahkan proses pengambilan keputusan. Walapun demikian, kondisi pasien dapat 
berbeda satu sama lain, sehingga pengambilan keputusan akhir perlu dipertimbangkan secara cermat pada setiap 
kondisi pasien.
Kata kunci: Antitrombotik, Antikoagulan, Antiplatelet, Gastrointestinal endoskopi
ABSTRACT
Endoscopic procedure is commonly used to make diagnosis or therapy. Endoscopy has risk on the procedure 
or after the procedure. Patient with antithrombotic therapy, both antiplatelet and/or anticoagulant, for underlying 
diseases has higher risk for bleeding and thromboembolic events in this procedure. The physician should consider 
risk and benefit for adjusting the antithrombotic therapy, in addition to minimize bleeding and thromboembolic 
events. For low risk procedure, adjustments in antithrombotic therapy usually not necessarily needed. For high 
risk procedure, there are several adjustments based on the type of medication and patient’s condition in specific. 
European Society of Gastrointestinal Guidelines Endoscopy (ESGE) and British Society of Gastrointestinal (BSG); 
American Society of Gastrointestinal Endoscopy (ASGE); and lastly Asian Pacific Association of Gastroenterology 
(APAGE) and Asian Pacific Society for Digestive Endoscopy (APSDE) have published guidelines to help physician 
to make decisions regarding antithrombotic therapy management during endoscopy. This article compares and 
contrasts the approach of each guideline, in design to help the decision-making process. However, each patient’s 
clinical condition may differ from one to another and should be considered carefully in making a final decision.
Keywords: Anticoagulant, Antiplatelet, Antithrombotic, Gastrointestinal endoscopy.
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INTRODUCTION
Endoscopic procedure is commonly used 
by physicians to establish diagnosis or direct 
therapy for gastrointestinal problems. This 
procedure can be classified as low risk and high 
risk procedure based on bleeding risk. Low 
risk procedures include diagnostic and biopsy, 
pancreas stenting, endoscopic ultrasound (EUS), 
and enteroscopy without polypectomy. High risk 
procedures include polypectomy, Endoscopic 
Retrograde Cholangio-pancreatography (ERCP) 
with sphincterotomy, dilatation of stricture, 
endoscopic submucosal dissection (ESD), and 
endoscopic mucosal resection (EMR).1–3
There are several preparations before 
endoscopic procedure can be performed, one 
of the preparation is adjustment therapy for 
patients with antiplatelet and/or anticoagulant 
therapy. Physician should consider the bleeding 
risk associated with endoscopic procedures and 
the potential thromboembolic risks of stopping 
antithrombotic therapy. Patients with these 
medications have higher thrombotic and bleeding 
risk. The provider should consider several factors 
for patients taking these medications who require 
endoscopy such as the urgency of the procedure, 
the bleeding risk both from endoscopic procedure 
and antithrombotic drugs, and the risk of 
thromboembolic event.2
European Society of Gastrointestinal 
Guidelines Endoscopy (ESGE), British Society 
of Gastrointestinal (BSG), American Society of 
Gastrointestinal Endoscopy (ASGE), Asian Pacific 
Association of Gastroenterology (APAGE), and 
Asian Pacific Society for Digestive Endoscopy 
(APSDE) have published guidelines to help 
physician make decisions regarding antithrombotic 
therapy management during endoscopy. The 
published guidelines are: (1) Guidelines in patients 
on antiplatelet or anticoagulant therapy, including 
direct oral anticoagulants: British Society of 
Gastroenterology (BSG) and European Society 
of Gastrointestinal Endoscopy (ESGE) guidelines, 
(2) The management of antithrombotic agents for 
patients undergoing GI endoscopy from ASGE, 
and (3) Management of patients on antithrombotic 
agents undergoing emergency and elective 
endoscopy: joint Asian Pacific Association of 
Gastroenterology (APAGE) and Asian Pacific 
Society for Digestive Endoscopy (APSDE) 
practice guidelines. This paper will review the 
comparison between BSG-ESGE, ASGE, and 
APAGE-APSDE guidelines.
LOW RISK ENDOSCOPY
All  guidel ines  expla in  the  use  of 
antithrombotic therapy, antiplatelet agents and 
anticoagulants during peri-endoscopic period, 
while there are several different approaches in 
evaluation for patients with these medications 
who require endoscopy. BSG-ESGE and 
APAGE-APSDE classify procedure based on low 




 - Diagnostic and biopsy 
procedure
 - Biliary or pancreatic 
stenting
 - Diagnostic EUS
 - Device-assisted 
enteroscopy without 
polypectomy
 - Diagnostic and biopsy procedure
 - ERCP with stent, without sphincterotomy
 - Enteroscopy
 - Capsule endoscopy
 - Enteral Stent
 - EUS without fine needle aspiration (FNA)
 - Argon Plasma Coagulation
 - Barrett’s ablation
 - Diagnostic endoscopy 
with biopsy
 - ERCP with stenting
 - EUS without FNA
 - Diagnostic push or device 
assisted enteroscopy
 - Capsule endoscopy
 - Esophageal, enteral, and 
colonic stenting
 - Argon plasma coagulation
Therapy  - P2Y12 receptor 
antagonist: continue 
therapy
 - Warfarin: continue 
therapy with monitoring 
of INR level
 - DOAC: reduce one dose 
in the morning of the 
procedure
 - Continue thienopyridines
 - Continue warfarin and NOAC
 - Continue  ASA/NSAID
 - Continue antiplatelet 
agents and/or 
anticoagulants
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risk or high risk of bleeding and ASGE classify 
based on urgency of the procedure to make 
decision on peri-endoscopic therapy.
Table 1 shows ASGE and APAGE-APSDE 
include more specific procedures compares 
to BSG-ESGE. The BSG-ESGE guidelines 
are more detailed in the adjustment therapy of 
P2Y12 receptor antagonist, warfarin, and Direct 
Oral Anti-Coagulant (DOAC), while ASGE and 
APAGE-APSDE do not mention changing therapy 
in low risk procedure. All guidelines recommend 
continuing warfarin, BSE-ESGE suggests to 
monitor the level of INR before the procedure, 
if INR within therapeutic range, continue daily 
dose of warfarin, if INR above therapeutic range 
but lower than 5, reduce daily dose until INR 
returns to therapeutic range. All guidelines also 
recommend to continue DOAC/NOAC, while 
BSE-ESGE specifically suggests reducing one 
dose in the morning of the procedure. Aspirin 
suggested to be continued since there is no 
evidence that aspirin or NSAIDs can increase 
the risk of bleeding after diagnostic, mucosal 
biopsy or polypectomy, but BSG-ESGE and 
APAGE-APSDE specifically mention there is an 
exception for endoscopic submucosal dissection 
(ESD), large colonic endoscopic mucosal 
resection (EMR) (>2 cm), upper gastrointestinal 
EMR, and ampullectomy, all antithrombotic 
agent should be stopped.1,3 Several studies show 
minimal risk of bleeding and no severe bleeding 
event occurs, both in diagnostic and mucosal 
biopsy endoscopy, even among patients taking 
antithrombotic agent.4–9 These results are in line 
with the guidelines recommendation.
HIGH RISK ENDOSCOPY
For high risk endoscopy, APAGE-APSDE 
has similar classification with BSG-ESGE and 
ASGE, but BSG-ESGE includes esophageal, 





 - ERCP with sphincterotomy
 - Ampullectomy
 - EMR/ESD
 - Therapy of varices
 - PEG
 - EUS with FNA
 - Dilatation of strictures
 - Esophageal, enteral, or 
colonic stenting
 - Polypectomy
 - ERCP with sphincterotomy
 - Ampullectomy
 - EMR/ESD
 - Therapy of varices
 - PEG/PEJ
 - EUS with FNA
 - Balloon enteroscopy
 - Endoscopic hemostasis
 - Tumor ablation
 - Cyst gastrostomy
 - Pneumatic/Bougie dilation
 - Polypectomy
 - ERCP with sphincterotomy
 - Ampullectomy
 - Therapy of varices
 - PEG/PEJ
 - EUS with FNA
 - Dilatation of strictures
Ultra High Risk 
Procedure - -
 - ESD
 - EMR (> 2 cm)
Therapy  - P2Y12 receptor antagonist:
1. Low risk condition*: stop 5 
days before endoscopy.
2. High risk condition*: stop 5 
days before endoscopy.
 - Warfarin:
1. Low risk condition**: stop 
5 days before endoscopy. 
2. High risk condition**: stop 
5 days before endoscopy; 
heparin bridging
 - DOAC:
1. Take last dose of drug ≥48 
hours before procedure
 - Stop P2Y12 receptor 
antagonist 5-7 days before 
endoscopy
 - Discontinue anticoagulant, 
restart warfarin on the 
same day (on low risk 
condition**) or bridging 
therapy (on high risk 
condition**)
 - Continue ASA/NSAID
 - Stop P2Y12 receptor antagonist 
5 days before.
 - Warfarin: 
1.  Low to moderate risk**: stop 
5 days before endoscopy. No 
heparin bridging
2. High risk condition**: stop 
5 days before endoscopy. 
Heparin bridging
 - Withhold DOACs 2 days 
beforehand
 - If the patient has cardiac events 
(ACS or PCI) <6 weeks, cancel 
the procedure
 - For ultra-high-risk procedure, 
patient should stop all 
antithrombotic agents.
*) Risk stratification based on thrombotic risk, Low Risk Condition: Ischemic Heart Disease without coronary stent, 
Cerebrovascular Disease, Peripheral Vascular Disease; High Risk Condition: Coronary Artery Stents (>12 months after 
inserting drug-eluting stent, >1 month after inserting metal coronary stent)
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enteral, or colonic stenting and ASGE include 
balloon enteroscopy, endoscopic hemostasis, 
tumor ablation, cyst gastrostomy, and pneumatic/
bougie dilation into high risk procedure as 
shown in Table 2. APAGE-APSDE specifically 
mention ESD and EMR more than 2 cm 
classified into ultra-high-risk procedure. For 
ultra-high-risk procedure, they recommend to 
stop all antithrombotic agent due to high risk of 
imbalance hemostasis. In general, all of guidelines 
recommend stopping P2Y12 receptor antagonist 
5 days before the procedure. BSG-ESGE detail 
more specific information for patient with 
“low risk” and “high risk” condition based on 
underlying cardiovascular disease. All guidelines 
suggest stopping warfarin 5 days before the 
procedure and adjustment therapy applied 
based on low or high risk patient’s condition. 
Heparin bridging therapy is recommended for 
patient with high risk of thromboembolic events 
who undergo high risk procedure. BSG-ESGE 
explain the bridging therapy can be started 
by substitution therapy with low molecular 
weight heparin (LMWH) 2 days after stopping 
warfarin, while APAGE-APSDE recommends 
using unfractionated heparin since it has shorter 
half-life. However, physician should be aware of 
the potential risk of bleeding since study shows 
bridge anticoagulation therapy is associated with 
high incidence of bleeding after polypectomy.10,11 
BSG-ESGE proposes to take last dose of 
DOAC at least 48 hours before the procedure in 
normal kidney function and for patients taking 
Dagibratan with CrCl 30-50 mL/min, it should be 
stopped at least 72 hours before the procedure or 
liaise with hematologist if patient with severely 
impaired renal function. Table 3 describes 
the adjustment of the time of stopping DOAC 
based on creatinine clearance levels and type of 
drugs by ASGE. APAGE-APSDE specifically 
recommend not to take Dabigratan at all, if CrCl 
below 30 mL/min.
Endoscopic polypectomy relatively has 
lower risk of bleeding and perforation compare 
to other high risk procedure.12 Intraprocedural 
bleeding of patients undergoing polypectomy 
only occurs in 0.5-2.2% of patients, the 
risk is getting higher along with the size of 
the polyp and this type of bleeding can be 
controlled immediately on procedure. Risk of 
postprocedural bleeding even rarer (0.3-0.6%) 
and more associated in patients with risk factor 
such as size, morphology, location of the polyp, 
and other comorbidities (age, hypertension, 
renal disease, use of anticoagulant).13,14 
Another studies indicated an increased risk of 
bleeding and thrombotic event on patient with 
anticoagulant and antiplatelet therapy who 
underwent polypectomy endoscopy.11,15–17
Postprocedural bleeding occurs in 5-7% 
patients who underwent EMR and generally 
identified within first 48 hours after the 
procedure.18–20 A study showed from 2715 patient 
who underwent therapeutic ERCP, 122 (4.5%) 
patients had bleeding complication and 69.7% 
of them occurs intraprocedural.21 Bleeding after 
EUS-FNA was found in 2.4% of cases on patients 
with antithrombotic therapy.22 The incidence of 
hemorrhagic events after gastric ESD ranges 
from 3% to 15.6%.23–35
RISK FOR THROMBOEMBOLIC EVENT 
IN PATIENTS WITH MECHANICAL HEART 
VALVE(S) OR VTE ON COAGULATION 
THERAPY
There are some differences in stratifying 
risk of thromboembolic event on patient on 
coagulation therapy. Table 4 shows comparison 
between BSG-ESGE, ASGE, and APAGE-
APSDE classification. In general, patients 
with severe underlying disease with other 
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comorbidities and recent cardiac events have 
higher risk for thromboembolism.
Previous studies have shown an increased 
occurrence for developing thromboembolic 
events after endoscopic procedure (OR: 
3.58) for patients relative to controls.36 Other 
factors such as rebleeding and anticoagulant 
management factors (e.g. INR correction, 
reversal agent use, and drug interruption) were 
associated with thromboembolic events.37 All 
guidelines recommend restarting the warfarin 
after the procedure since studies show there is an 
association between the resumption of warfarin 
and reduction of thromboembolic events.38 
However, there is no exact time to restart the 
warfarin therapy. BSG-ESGE recommends 
restarting daily dose warfarin on the evening 
after the procedure, while APAGE-APSDE 
recommends restarting the warfarin therapy 
after 3 days.
CONCLUSION
All guidelines classify patients based on 
thromboembolic risk and classified procedure 
based on bleeding risk. They also described 
whether antithrombotic therapy needs to be 
stopped or not, but differ in the detail. For all 
procedure, Aspirin should be continued with 
some exception, where special consideration 
should be applied in patients requiring ESD, large 
colonic EMR (>2cm), upper gastrointestinal 
EMR, and ampullectomy. For low risk procedure, 
all antithrombotic therapy can be continued, 
whereas BSG-ESGE recommends monitoring 
INR levels carefully. For high risk procedure, 
all guidelines stratify patients based on the 
risk of thromboembolic events, but in different 
approaches, on the other hand, the adjustment 
therapy is quite similar. P2Y12 receptor inhibitor 
should be stopped at least 5 days before the 
procedure, BSG-ESGE has more consideration 
Table 4. Risk for thromboembolism of patient on coagulation therapy
BSG-ESGE ASGE APAGE-APSDE
VTE Low Risk
 - Atrial fibrillation without 
valvular disease
 - >3 months after venous 
thromboembolism
 - Thrombophilia 
syndromes
High Risk
 - Atrial fibrillation and 
mitral stenosis




 - >12 months previous 
and no other risk factor
Medium Risk
 - VTE within the past 3-12 
months
 - Non-severe 
thrombophilia
 - Recurrent VTE
 - Active cancer
High Risk
 - <3 months from previous 
VTE
 - Severe thrombophilia
Moderate to Low Risk
 - ACS or PCI >6 months 
ago
 - Stable coronary arterial 
disease
High Risk
 - ACS or PCI 6 weeks-6 
months ago
 - Non-valvular atrial 
fibrillation
 - <3 months after VTE
 - Severe thrombophilia
Very High Risk
 - ACS or PCI <6 weeks
Mechanical Heart Valve(s) Risk
 - Prosthetic metal heart 
valve in aortic position
 - Xenograft heart valve
High Risk
 - Prosthetic metal heart 
valve in mitral position
 - Prosthetic metal heart 
valve and AF.
Low Risk
 - Bileaflet aortic valve 
prosthesis without AF
Medium Risk
 - Bileaflet aortic valve 
prosthesis with risk 
factor (AF, CVA or TIA, 
hypertension, diabetes, 
CHF, Age >75 years)
High Risk
 - Mitral valve prosthesis
 - Caged ball or tilting disc 
aortic valve prosthesis
 - Recent CVA or TIA 
(within 6 months)
High Risk
 - Prosthetic valve with 
atrial fibrillation
 - Metallic mitral valve.
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for patient with history of having drug eluting 
stent or metal stent. All guidelines recommend 
warfarin should be stopped at least 5 days before 
the procedure and should be restarted after the 
procedure to minimize thromboembolic events. 
Patients with high risk thromboembolic events 
are recommended to have bridging therapy, but 
we should be aware of potential risk of delayed 
bleeding after the procedure. DOAC should be 
stopped in patients with high risk procedure 
at least 48 hours or maybe more in patients 
with impaired renal function. In the end, the 
decision to adjust antithrombotic therapy has to 
be individualized in consideration of patient’s 
condition and risk of the procedure.
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